Seminar
Indicates that handouts are available
Friday, February 28, 2014
5:15 PM-6:15 PM
1901
Allergen Immunotherapy or Omalizumab in Asthma: When to Use Which? TICKETED
Session Details
Friday, February 28, 2014: 5:15 PM-6:15 PM
Marriott South Tower, Level 3, Balboa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Thomas B. Casale , MD FAAAAI
Jonathan Corren , MD
Learning Objectives:
- Review efficacy of IT in asthma and safety of AIT in moderate-severe asthma
- Review studies of omalizumab alone and in combination with AIT in asthma
- Make recommendations on individual use of these drugs and in combination for asthma
1902
When is an Elevated IgE Level a Sign of Immunodeficiency? TICKETED
Session Details
Friday, February 28, 2014: 5:15 PM-6:15 PM
Marriott South Tower, Level 3, Mission Hills
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Alexandra F. Freeman , MD
Hans D. Ochs , MD
Learning Objectives:
- Review the differential diagnosis of an elevated IgE level
- Discuss the work up necessary in patients with elevated IgE levels
- Review the Hyper IgE syndromes
1903
How to Assess and Manage a Child with Multiple Positive Environmental and Food Allergy Tests TICKETED
Session Details
Friday, February 28, 2014: 5:15 PM-6:15 PM
Marriott South Tower, Level 3, Cardiff
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Sami L. Bahna , MD DrPH FAAAAI
Anna H. Nowak-Wegrzyn , MD FAAAAI
Learning Objectives:
- Explain the prevalence and difference between classic food allergies and pollen-food allergy syndrome
- Describe the utility of skin prick, fresh food skin prick, serum specific IgE testing, component resolved diagnostics and oral food challenge in assessment of complex patients with multiple food and environmental sensitizations
- Discuss the management of complex patients with multiple food and environmental sensitivities and/or allergies
1904
So the Patient Has Eosinophilia: What Next? TICKETED
Session Details
Friday, February 28, 2014: 5:15 PM-6:15 PM
Marriott South Tower, Level 1, Point Loma
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Amy D. Klion , MD
Catherine R. Weiler , MD PhD FAAAAI
Learning Objectives:
- Review diagnosis of various hypereosinophilic syndromes
- Describe identification of secondary eosinophilia
- Discuss therapeutic approaches to hypereosinophilic syndrome
Saturday, March 1, 2014
7:00 AM-8:00 AM
2001
Microbiota and Asthma TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon D
1.00 CME/ 1.20 CE
Primary Discussion Leader:
Yvonne Huang , MD
Learning Objectives:
- Review the importance of the microbiota in asthma and allergic disorders
- Discuss the dangers of inappropriate antibiotic use on the microbiota
- Describe fostering a healthy microbiota
2002
Provocative Testing for Exercise-Induced Asthma: Methacholine vs. Mannitol vs. Exercise TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon E
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Donald W. Cockcroft , MD FAAAAI
John M. Weiler , MD FAAAAI
Learning Objectives:
- Contrast indications/contraindications for bronchoprovocation challenges in patients with EIB
- Compare the strengths and weaknesses of each in the evaluation of hyper-reactivity
- Evaluate methacholine and mannitol challenge as potential tests for monitoring asthma treatment
2004
There's an App for That: Using Smart Phones, Tablets and Web Tools for Clinical Practice TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon G
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Tao T. Le , MD MHS FAAAAI
Melinda M. Rathkopf , MD FAAAAI
Learning Objectives:
- Describe the various device options and platforms available to the clinician
- Discuss the various apps available for the various devices and how to maximize their use
- Identify web tools useful in the allergy practice
2005
Immunizing the Immunodeficient Patient TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Balboa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Francisco A. Bonilla , MD PhD FAAAAI
M. Louise Markert , MD PhD FAAAAI
Learning Objectives:
- Identify laboratory findings that may predict when live viral vaccinations may be administered to patients with cellular immunodeficiency
- Review factors involved in timing of live viral vaccinations after immunosuppressive medications
- Discuss vaccinations and timing for patients with asplenia or scheduled splenectomy
2007
How to Be a Mold Sleuth TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Cardiff
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Anupma B. Dixit , PhD
H. James Wedner , MD FAAAAI
Learning Objectives:
- Discern the quality of building inspection reports regarding water damage and mold colonization in housing.
- Interpretation of mold sampling data to assess the significance of occupant exposure to molds indoors.
2008
Pathogenic Bacteria and Viral Illness: Are They Associated? What the Microbiome Tells Us TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Del Mar
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
James E. Gern , MD FAAAAI
Kirsten Kloepfer , MD
Learning Objectives:
- Describe the association between pathogenic bacteria and asthma exacerbations
- Discuss potential mechanisms for viral infections to promote infections with pathogenic airway bacteria
- Discuss potential treatment implications related to bacterial infections, wheezing illnesses and exacerbations of asthma
2009
Aspirin and Antibiotic Desensitization TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Miramar
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Anahita F. Dioun , MD FAAAAI
Catherine R. Weiler , MD PhD FAAAAI
Learning Objectives:
- Describe what is needed to perform a desensitization in the office
- Discuss the desensitization of aspirin allergic patients
- Review the desensitization of antibiotic allergic patients
2010
Fifty Shades of Eosinophilic Esophagitis: Identifying the Phenotypes TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Point Loma
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Juan Pablo Abonia , MD
Mirna Chehade , MD MPH
Learning Objectives:
- Demonstrate the ability to identify EoE co-morbidities
- Recognize when to suspect EoE given the medical history, whenever esophageal eosinophilia is found.
- Learn how to investigate for other potentially associated diseases with EoE that require medical attention.
2011
Getting Ready for ICD-10: Cracking the Code TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Solana
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Priya J. Bansal , MD FAAAAI
Marshall P. Grodofsky , MD FAAAAI
Learning Objectives:
- Describe the differences between ICD-10 and ICD-9-CM
- Discuss the impact of ICD-10 on billing and coding
- Identify strategies for implementing ICD-10 in clinical practice
2012
Component-Resolved Diagnosis for Inhalant Allergies TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Santa Rosa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Reto Crameri , PhD
Peter Schmid-Grendelmeier , MD PhD
Learning Objectives:
- Describe cross-reactivity between various inhalant allergens and food allergens
- Define predictive value of CRD for disease outcome
- Identify better selection criteria for allergen-specific immunotherapy
2013
Cockroach Immunotherapy TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, La Costa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Luisa Karla P. Arruda , MD PhD FAAAAI
William W. Busse , MD FAAAAI
Learning Objectives:
- Discuss epidemiologic studies on cockroach allergy, including outcomes of abatement procedures
- Review characteristics of cockroach allergens and composition of cockroach extracts currently available
- Discuss ongoing and published studies on cockroach immunotherapy and new perspectives for treatment of cockroach allergy
2014
Alternative Pathways of Antigen-Mediated Anaphylaxis TICKETED
Session Details
Saturday, March 1, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, Catalina
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Mary Beth Hogan , MD FAAAAI
Wei Zhao , MD PhD FAAAAI
Learning Objectives:
- Review the traditional pathway of anaphylaxis
- Discuss the role of basophils and neutrophils in the pathogenesis of anaphylaxis
- Distinguish IgE(mast cell) mediated anaphylaxis from IgG/Platelet Activating Factor as an alternative mechanism of anaphylaxis
12:30 PM-1:30 PM
2501
The Evolution of Childhood Wheezing to Asthma TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 3, Marina Ballroom Salon D
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Leonard B. Bacharier , MD FAAAAI
Bradley E. Chipps , MD
Learning Objectives:
- Determine the diagnostic criteria for varied phenotypic expression of childhood asthma
- Examine the progression of immunopathologic events in the development of childhood asthma
- Examine the implication for treatment given the varied immunopathologic and phenotypic expressions
2502
Performing and Interpreting Spirometry: Understanding and Implementing the ATS/ERS Guidelines TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 3, Marina Ballroom Salon E
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
James M. Quinn , MD FAAAAI
Kevin M. White , MD
Learning Objectives:
- Identify the source and relevance of the ATS/ERS guidelines for lung function testing
- Discuss the ATS/ERS recommendations for correct performance of spirometry
- Identfy ATS/ERS guidelines to interpret spirometry and classify the severity of identified abnormalities.
2503
Hereditary Angioedema: Diagnosis and Management TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 3, Marina Ballroom Salon F
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Mark S. Dykewicz , MD FAAAAI
Andrew J. MacGinnitie , MD PhD
Learning Objectives:
- Review the mechanism of HAE
- Discuss how and when to use the new therapies for HAE
- Describe how to improve outcomes of your patient's with HAE
2504
Making the Most of Your EMR: Meeting Meaningful Use TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 3, Marina Ballroom Salon G
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Priya J. Bansal , MD FAAAAI
A. Sean McKnight , MD FAAAAI
Learning Objectives:
- Discuss tips for optimizing your current EMR
- Discuss current state of Meaningful Use government incentive payments
- Discuss clinical quality measures and PQRI reporting with your EMR
2505
When Should Bone Marrow Transplantation be Considered in Primary Immunodeficiency? TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 3, Balboa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Rebecca A. Marsh , MD
Elena E. Perez , MD PhD FAAAAI
Learning Objectives:
- Review the primary immunodeficiency diseases for which BMT can be a curative treatment
- Discuss how soon after diagnosis a patient with certain immunodeficiency disorders should be referred to a BMT center
- Review any therapies to be avoided prior to a patient going to transplant
2506
Viral Infections in the Allergic Host: What Factors May Be Synergistic? TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 3, Mission Hills
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Josh L. Kennedy , MD
Eva Kathryn Miller , MD
Learning Objectives:
- Evaluate the innate immune response to viral infection in the exacerbating asthmatic, particularly the evidence of a deficient or overactive response
- Discuss the role of the epithelium in asthmatic responses to viral infection
- Evaluate the role of allergy by examining the evidence that IgE responses are important predictors of asthma exacerbations
2507
Biomass Smoke: Alternative Energy or Pollutant Source? TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 3, Cardiff
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Patricia Mason Fritz
Alisa M. Smith , PhD FAAAAI
Learning Objectives:
- Recognize the emergence of a potentially significant source of community (neighborhood) air pollution
- Discuss the continuum and coherence of health effects from exposure to combustion emissions
- Analyze the role of ambient air pollution on the health of non-urban populations
2508
The Intricacy of Penicillin Allergy Evaluation TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 3, Del Mar
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Eric M. Macy , MD FAAAAI
Miguel A. Park , MD
Learning Objectives:
- Discuss the different components of the penicillin skin test
- Discuss how the different components of the penicillin skin test affect the negative predictive value
- Discuss the role of oral challenges to penicillin and/or amoxicillin in the evaluation of penicillin allergy
2509
Performance of Oral Food Challenges in the Office Setting TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 3, Miramar
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
S. Allan Bock , MD FAAAAI
Justin M. Skripak , MD
Learning Objectives:
- Describe and perform food challenges in their own practices
- Review the practical aspects of how to carry out a typical food challenge in the office
- Discuss how to select patients for extensively heated milk and egg challenges and how to perform those challenges
2510
Quality Improvement and Patient Safety in Allergy Practice TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 1, Point Loma
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Matthew A. Rank , MD FAAAAI
Brad J. McClimon , MD
Learning Objectives:
- Discuss the need for allergists to consider, plan and perform quality projects
- Discuss fundamental principles guiding quality improvement of allergic/immunologic diseases in the United States
- Discuss potential quality improvement opportunities that could positively influence the outcomes of allergy, asthma and immunology education, research and patient care at the local and national level
2512
Immunotherapy with Immunomodulator Therapy: Which Work and Which Do Not? TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 1, Santa Rosa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Peter S. Creticos , MD FAAAAI
Mohamed H. Shamji , BSc MSc PhD
Learning Objectives:
- Review new data on the combination of immunotherapy and certain immunomodulators
- Discuss the the possible mechanisms that might account for these findings, analyzing the mechanisms of immunotherapy in a new light
2513
Evaluating Experimental Models of Allergic Rhinitis TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 4, La Costa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Anne K. Ellis , MD MSc FAAAAI
Martin Wagenmann , MD FAAAAI
Learning Objectives:
- Describe the most commonly used methodologies for experimental nasal allergen challenge in the investigation of allergic rhinitis
- Describe the commonly used methodologies utilized in environmental exposure unit-type studies of allergic rhinitis
- Describe the advantages and disadvantages of both experimental models pertaining to the study of allergic rhinitis
2514
Food Allergy and the Mucosal B Cell TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 4, Catalina
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Cathryn R. Nagler , PhD
Duane R. Wesemann , MD PhD
Learning Objectives:
- Discuss how commensal organisms and dietary antigens may shape the pre-immune antibody repertoire
- Review the known mechanisms underlying immune tolerance to gut luminal antigens
- Describe the mechanisms regulating antibody affinity maturation and IgH class switch recombination to IgE
2515
Prostaglandins: Regulatory Lipid Mediators TICKETED
Session Details
Saturday, March 1, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 4, Coronada
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Darryl C. Zeldin , MD
Weisong Zhou , PhD
Learning Objectives:
- Define the role of prostaglandins in vascular remodeling and allergic lung inflammation
- Describe the role of prostaglandins in regulating T cell differentiation and function
- Describe the role of prostaglandins on allergen-induced immune tolerance
Sunday, March 2, 2014
7:00 AM-8:00 AM
3002
Use of Cytokine Inhibitors in Severe Asthma TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon E
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Jonathan Corren , MD
Sally E. Wenzel , MD FAAAAI
Learning Objectives:
- Review and understand the roles that specific cytokines play in asthma
- Review trials of various agents (anti-TNF, anti-IL4, anti-IL13, anti-IL5, anti-IL17, anti-IL9) if asthma
- Explore subtypes of asthma where these agents might best be used
3003
How Many Eosinophils are Too Many? TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon F
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Paneez Khoury , MD
Princess U. Ogbogu , MD FAAAAI
Learning Objectives:
- Review the criteria for eosinophilia
- Discuss the differential diagnosis of eosinophilia
- Review the work-up for an increase eosinophil count
3004
Social Media for Allergy/Immunology Practice: Let's Do It! TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon G
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Sakina S. Bajowala , MD FAAAAI
Nathaniel D. Hare , MD FAAAAI
Learning Objectives:
- Discuss how to set up a Twitter account and how to use it to connect with patients and colleagues
- Discuss how to set up a Facebook professional page
- Describe how to use YouTube to embed and record videos to maintain an interactive website for your practice
3005
Update on Testing for Primary Immunodeficiency Diseases TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Balboa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
John M. Routes , MD FAAAAI
Kathleen E. Sullivan , MD PhD FAAAAI
Learning Objectives:
- Review novel testing for recurrent or unusual infections
- Discuss genetic testing for primary immunodeficiency diseases
- Discuss future testing for primary immunodeficiency
3006
Let's Take the Myth-stery Out of Mold TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Mission Hills
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
James J. Anderson , MLT
Peter J. Pityn , PhD
Learning Objectives:
- Provide evidence that the risk of mold is often overstated, misstated, or misunderstood
- Learn of the true risk presented by mold
- Explore issues with mold assessments & everyday mold exposure
3007
Environmental Microbiomes TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Cardiff
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Christina E. Ciaccio , MD FAAAAI
Brett J. Green , PhD
Learning Objectives:
- Explore the human microbiome and allergic disease
- Discuss the normal indoor microbiome and factors that cause alterations in the typical structure
3008
Medical Management of Eosinophilic Esophagitis in Adults TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Del Mar
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Mark Holbreich , MD FAAAAI
Javed Sheikh , MD FAAAAI
Learning Objectives:
- Show the appropriate use of diet in EoE management in adults
- Demonstrate the different medications and become familiar with dose and delivery
- Describe the pros and cons of esophegeal dilation in EoE
3009
Mastocytosis Mimics: Cutting Through the Clutter TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Miramar
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Joseph H. Butterfield , MD FAAAAI
Melody C. Carter , MD
Learning Objectives:
- List the criteria for diagnosing systemic mastocytosis
- Recognize the variety of mast cell activation disorders and the criteria needed for a true diagnosis of mast cell activation syndrome
- Describe the differential diagnostic possibilities when faced with a patient with symptoms suggestive of systemic mastocytosis or mast cell activation syndrome
3010
Optimizing the Allergist's Expertise in Asthma Adherence TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Point Loma
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Bruce G. Bender , PhD FAAAAI
L. Keoki Williams , MD MPH FAAAAI
Learning Objectives:
- Discuss an appreciation for the prevalence and implications of suboptimal adherence in asthma
- Develop clues which may suggest suboptimal adherence
- Discuss strategies to facilitate optimal controller use in specific asthmatic patients
3011
Is Immunotherapy Getting Safer? Updated Information on Various Forms of Immunotherapy and How to Improve TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Solana
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Tolly Epstein , MD MS
Michael S. Tankersley , MD FAAAAI
Learning Objectives:
- Summarize current evidence regarding the incidence of fatal reactions to SCIT
- Critically assess new evidence characterizing risk factors associated with SCIT anaphylaxis that may be applied to optimize safety protocols
- Discuss the necessity of thirty minute waiting period after SCIT injections
3012
Clinical Conundrums in Chronic Rhinosinusitis TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Santa Rosa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Rakesh Chandra , MD
Raymond G. Slavin , MD MS FAAAAI
Learning Objectives:
- Utilize an evidence-based approach to the diagnosis and treatment of chronic rhinosinusitis
3013
Understanding How Allergic Responses End: The Allergy Resolvome TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, La Costa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Koichiro Asano , MD
Ariel Munitz , PhD
Learning Objectives:
- Identify factors involved in resolution of inflammation
- Review lipid mediators', IL-10 and endocannabinoids' mechanism of action in the resolution of inflammation
3014
Inhibitory Receptors on Allergy Effector Cells: New Therapeutic Targets TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, Catalina
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Bruce S. Bochner , MD FAAAAI
Francesca Levi-Schaffer , PhD FAAAAI
Learning Objectives:
- Discuss the mechanisms of three different inhibitory receptors pertinent for asthma
- Describe efforts to therapeutically target these receptors
3015
Parasites, Allergy and Asthma TICKETED
Session Details
Sunday, March 2, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, Coronada
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Luisa Karla P. Arruda , MD PhD FAAAAI
Thomas A.E. Platts-Mills , MD PhD FAAAAI
Learning Objectives:
- Review outcomes of clinical trials conducted with parasites to treat patients with asthma or rhinitis
- Discuss epidemiologic studies on parasites, allergy and asthma carried out in different areas of the world and with different populations
- Discuss mechanisms by which parasite infection may influence immune responses underlying allergy and asthma and the role of parasite infections in total and specific IgE
Monday, March 3, 2014
7:00 AM-8:00 AM
4001
Asthma and the Older Adult TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon D
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Alan P. Baptist , MD MPH FAAAAI
Paula L. Busse , MD FAAAAI
Learning Objectives:
- Compare how asthma symptoms and spirometry may differ in older adults compared to younger populations
- Identify unique factors associated with poor asthma control and quality of life in older adults
- Discuss the optimal pharmacologic and non-pharmacologic management strategies for older adults with asthma
4002
Use of Biomarkers in Severe Asthma TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon E
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Jonathan Corren , MD
Faoud T. Ishmael , MD PhD FAAAAI
Learning Objectives:
- Review and understand specific markers (blood and sputum eosinophils, FeNO, periostin, urine leukotrienes, EBT)
- Describe the relationship of these markers to specific asthma phenotypes and endotypes
- Explore the use of these markers as predictors of efficacies of specific therapies
4003
Evaluation of Autoinflammatory Disorders in Children TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon F
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Ronit Herzog , MD FAAAAI
Lu Yao , MD
Learning Objectives:
- Discuss the clinical and laboratory presentation of children with auto-inflammatory disorder
- Describe the pathophysiology of auto-inflammatory disorder in children
- Discuss the workup and management of children with suspected auto-inflammatory disorder
4004
Selection and Implementation of an Electronic Medical Record TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Marina Ballroom Salon G
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
David J. Shulan , MD FAAAAI
Richard L. Wasserman , MD PhD FAAAAI
Learning Objectives:
- Discuss why one would choose an EHR
- Describe how to pick an EHR
- Identify the needed procedures in implementing an EHR
4006
How to Get Your K Award Applications by a Mock Study Section TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Mission Hills
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Nora A. Barrett , MD FAAAAI
Lawrence J. Prograis Jr. , MD
Joshua A. Boyce , MD FAAAAI
Learning Objectives:
- Describe the peer review process for K award applications
- Describe common strengths and weaknesses in K award applications as identified by reviewers
- Apply knowledge of common review concerns to the preparation of a competitive K award application
4008
Diagnosing an Allergy to Galactose Alpha 1,3 Galactose TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Del Mar
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Scott P. Commins , MD PhD
Maya R. Jerath , MD PhD
Learning Objectives:
- Describe the clinical presentation of alpha gal food allergy
- Identify how to diagnose and manage alpha gal food allergy
4009
Non-IgE-Mediated Food Allergies TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Miramar
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Jean-Christoph Caubet , MD
Anna H. Nowak-Wegrzyn , MD FAAAAI
Learning Objectives:
- Present a variety of patient cases posing diagnostic dilemmas in non-IgE food allergy
- Discuss the utility of feeding history, skin prick, serum specific IgE testing and oral food challenge in diagnosing complex patients with possible GI food allergies
4010
Outcomes and Quality Measures in Allergy Practice and Research TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Point Loma
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Chitra Dinakar , MD FAAAAI
Kaiser G. Lim , MD FAAAAI
Learning Objectives:
- Identify the most appropriate outcomes measures for assessment of quality practice in asthma and other allergic diseases
- Learn how to design an outcomes study for asthma
4011
Proactive Management of Food Allergies in Schools TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Solana
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Alton Lee Melton Jr. , MD
Michael C. Young , MD FAAAAI
Learning Objectives:
- Identify activities and situations in the school setting that place allergic students at risk for accidental food allergen exposures
- Discuss recommendations for schools and parents regarding best practices for treating reactions that do occur and proactively reducing the risk for accidental food allergen exposures
4012
New Aspects of the Involvement of B and T Cells in the Mechanisms of Immunotherapy TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Santa Rosa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Mubeccel Akdis , MD PhD
Mark Larche , PhD
Learning Objectives:
- Review new data of regulatory T cell involvement in the immunologic reactions documented after immunotherapy
- Review new data of regulatory B cell involvement in the immunologic reactions documented after immunotherapy
- Discuss the interactions between both these systems
4013
Chronic Rhinosinusitis Subtypes and Treatment Implications TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, La Costa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Amber U. Luong , MD PhD
Rodney J. Schlosser , MD
Learning Objectives:
- Describe the classification of sinusitis
- Describe the clinical subtypes of chronic rhinosinusitis
- Explain the different non-surgical treatment options for the different chronic rhinosinusitis subtypes
4014
How Do Antigens Become Allergens? TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, Catalina
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Angela Haczku , MD PhD FAAAAI
Anne Sperling , PhD
Learning Objectives:
- Describe how the immune system recognizes innocuous allergens
- Discuss dendritic cells, important sentinel cells in allergy
- Review the development of therapeutic agents that could fine tune the dendritic cell response
4015
Th17 Cells, Neutrophils and Severe Asthma TICKETED
Session Details
Monday, March 3, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, Coronada
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Dawn C. Newcomb Baker , PhD
R. Stokes Peebles Jr. , MD FAAAAI
Learning Objectives:
- Describe the role of STAT signaling in Th17 cell development and cytokine expression
- Define the role of gender in Th17 cell differentiation and cytokine expression in patients with severe asthma
- Discuss the role of IL-17A on structural cells in the airway
4:45 PM-5:45 PM
4822
Smoking and Asthma: Not Just Blowing Smoke TICKETED
Session Details
Monday, March 3, 2014: 4:45 PM-5:45 PM
Marriott South Tower, Level 3, Balboa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Riccardo Polosa , MD PhD FAAAAI
Mark F. Sands , MD FAAAAI
Learning Objectives:
- Describe the pathophysiologic consequences of tobacco smoking upon the asthmatic
- Recognize the effect of tobacco smoke on the lung from fetus through adult life
- Describe effective smoking cessation interventions
4823
Gene Therapy for Primary Immunodeficiency Disorders: Where are We in 2014? TICKETED
Session Details
Monday, March 3, 2014: 4:45 PM-5:45 PM
Marriott South Tower, Level 3, Mission Hills
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Matthew Porteus , MD PhD
Fabio Candotti , MD
Learning Objectives:
- Review the primary immunodeficiency disorders for which gene therapy is a treatment option
- Discuss the mechanism of gene therapy
- Discuss limitations and risks associated with gene therapy
4824
Occupational Respiratory Diseases TICKETED
Session Details
Monday, March 3, 2014: 4:45 PM-5:45 PM
Marriott South Tower, Level 3, Cardiff
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
André Cartier , MD FAAAAI
Susan M. Tarlo , MBBS FAAAAI
Learning Objectives:
- Recognize the history clues pointing to potential work-related asthma
- Develop familiarity with the approach needed to establish the diagnosis of occupational asthma
- Compare the strengths and weaknesses of the tools available to establish work-relatedness
4826
Exercise-Induced Anaphylaxis and Food-Dependent Exercise-Induced Anaphylaxis TICKETED
Session Details
Monday, March 3, 2014: 4:45 PM-5:45 PM
Marriott South Tower, Level 1, Point Loma
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Anna M. Feldweg , MD
Kirsi M. Jarvinen-Seppo , MD PhD
Learning Objectives:
- Review the most common clinical presentations of EIAn and typical foods that can trigger FD-EIAn
- Identify recent publications relevant to EIAn and FD-EIAn
- Increase understanding of treatment options for EIAn and FD-EIAn
4827
Physical Urticarias TICKETED
Session Details
Monday, March 3, 2014: 4:45 PM-5:45 PM
Marriott South Tower, Level 1, Solana
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Mario Geller , MD FAAAAI
Karen S. Hsu Blatman , MD
Learning Objectives:
- Identify physical urticarias
- Evaluate and educate patients with physical urticarias
- Manage and treat physical urticarias with the recent data
4828
Advanced Coding for the Allergist TICKETED
Session Details
Monday, March 3, 2014: 4:45 PM-5:45 PM
Marriott South Tower, Level 1, Santa Rosa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Noga Askenazi , MD FAAAAI
Gary N. Gross , MD FAAAAI
Learning Objectives:
- Discuss the use of codes pertinent to allergy/immunology practice
- Describe details of coding for patients' allergy testing and immunotherapy
4829
Immunodeficiencies Discovered in the Last Five Years TICKETED
Session Details
Monday, March 3, 2014: 4:45 PM-5:45 PM
Marriott South Tower, Level 4, La Costa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Francisco J. Espinosa-Rosales , MD
Gulbu Uzel , MD
Learning Objectives:
- Discuss the new primary immunodeficiency diseases with a focus on those described during the past five years
- Appreciate the newer technologies used for discovery of these and future disorders
- Appreciate the expanding overlap between immunodeficiency and inflammatory disorders
4830
Management of Children and Adult Patients with Atopic Dermatitis TICKETED
Session Details
Monday, March 3, 2014: 4:45 PM-5:45 PM
Marriott South Tower, Level 4, Catalina
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Dagmar Simon , MD
Jon M. Hanifin , MD FAAAAI
Learning Objectives:
- Describe the presentation, pathophysiology and complications of atopic dermatitis
- Discuss the management of these patients, including their education
- Discuss possible therapeutic consequences due to new insights into the pathogenesis of atopic dermatitis
Tuesday, March 4, 2014
7:00 AM-8:00 AM
5001
Corticosteroid Resistance in Asthma TICKETED
Session Details
Tuesday, March 4, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Balboa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Elena Goleva , PhD
Faoud T. Ishmael , MD PhD FAAAAI
Learning Objectives:
- Discuss current approaches for clinical evaluation of potential insensitivity to oral and inhaled CS
- Describe glucocorticoid receptor function and current understanding of the molecular pathways that lead to CS insensitivity; Explain the interaction of the glucocorticoid receptor with other steroid receptor regulated pathways, i.e. vitamin D, sex hormones, etc.
- Discuss management of patients with suspected CS insensitivity and alternative therapeutic strategies for these patients
5002
Rethinking Allergen Avoidance TICKETED
Session Details
Tuesday, March 4, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Mission Hills
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Elizabeth Matsui , MD
Euan R. Tovey , PhD
Learning Objectives:
- Define current guidelines for allergen avoidance in asthma management
- Describe methods of reducing allergen exposure and evidence based studies of their effectiveness
- Discuss new strategies for allergen avoidance that take into account the complex interactions between allergens, the innate immune system and genetic markers
5003
Role of Allergy in Atopic Dermatitis TICKETED
Session Details
Tuesday, March 4, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 3, Cardiff
1.00 CME/ 1.20 CE
Primary Discussion Leader:
Johannes Ring , MD PhD FAAAAI
Learning Objectives:
- Review practical relevance of aero-food and contact allergic reactions in triggering flairs of AD
- List practical tips for management with regard to restoring disturbed barrier function in AD
5004
Cases of Patients with Chronic Cough TICKETED
Session Details
Tuesday, March 4, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Point Loma
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Mandel R. Sher , MD FAAAAI
Gary J. Stadtmauer , MD FAAAAI
Learning Objectives:
- Describe various diagnostic and treatment techniques for patients with chronic cough.
5005
New Insights into IgE Biology TICKETED
Session Details
Tuesday, March 4, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Solana
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Hannah J. Gould , PhD
Toshiaki Kawakami , MD, PhD
Learning Objectives:
- Identify the regulation of IgE production in B cells
- Describe the acquisition of IgE by tissue mast cells
- Identify the effects of IgE activation on tissue mast cells in inflammation
5006
Exhaled NO: Time to Clear the Air! TICKETED
Session Details
Tuesday, March 4, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 1, Santa Rosa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Chitra Dinakar , MD FAAAAI
Stanley J. Szefler , MD FAAAAI
Learning Objectives:
- Discuss the application of eNO in the context of ATS guidelines and AAAAI/ACAAI position statements
- Recognize the relationship between the levels of evidence and practice guidelines for clinical eNO use
- Explain potential weaknesses/strengths of eNO for managing asthmatics
5008
Challenges of Managing Multiple Food Allergies TICKETED
Session Details
Tuesday, March 4, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, Catalina
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Julie Wang , MD FAAAAI
Michael C. Young , MD FAAAAI
Learning Objectives:
- Identify the diagnostic and management challenges of multiple food allergies
- Recognize the nutritional, feeding and social risk factors
- Develop and implement a feeding plan for adequate nutrition, feeding skill and social development of children with multiple food allergies
5009
SLIT vs. SCIT in Children TICKETED
Session Details
Tuesday, March 4, 2014: 7:00 AM-8:00 AM
Marriott South Tower, Level 4, Coronada
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Giovanni Passalacqua , MD
David P. Skoner , MD
Learning Objectives:
- Summarize experience with SLIT and compare and contrast its safety/efficacy versus SCIT
- Appreciate recent data describing SLIT
- Appreciate methodologic variation in SLIT
12:30 PM-1:30 PM
5521
Approach to the Evaluation of Immunodeficiency in Adults TICKETED
Session Details
Tuesday, March 4, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 1, Point Loma
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Adina Kay Knight , MD FAAAAI
Joyce E. Yu , MD
Learning Objectives:
- Discuss the workup and management of adults with suspected immunodeficiency
- Compare and contrast the differential diagnosis for hypogammaglobulinemia in adult patients
- List key differences between the immunodeficiency diagnostic spectrum in adults vs. adolescents and children
5523
Novel Therapies for Chronic Urticaria and Angioedema TICKETED
Session Details
Tuesday, March 4, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 1, Santa Rosa
1.00 CME/ 1.20 CE
Primary Discussion Leader:
David H. Dreyfus , MD PhD FAAAAI
Learning Objectives:
- Discuss novel therapy for chronic urticaria and angioedema
- List novel diagnostic testing for chronic urticaria and angioedema
- Review practical considerations for application of novel therapy and diagnosis
5524
Tree Nut and Peanut: Complexity in Cross-Reactivity TICKETED
Session Details
Tuesday, March 4, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 4, La Costa
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Soheila J. Maleki , PhD
Suzanne S. Teuber , MD FAAAAI
Learning Objectives:
- Distinguish between clinical cross-reactivity and in vitro cross-reactivity
- List the main seed storage proteins involved in cross-reactivity
- Review the closely related tree nuts that are often clinically cross-reactive
5525
Chronic Rhinosinusitis Subtypes and Implications for Treatment TICKETED
Session Details
Tuesday, March 4, 2014: 12:30 PM-1:30 PM
Marriott South Tower, Level 4, Catalina
1.00 CME/ 1.20 CE
Primary Discussion Leaders:
Joseph K. Han , MD
Amber U. Luong , MD PhD
Learning Objectives:
- Describe the classification of sinusitis
- Describe the clinical subtypes of chronic rhinosinusitis
- Explain the different non-surgical treatment options for the different chronic rhinosinusitis subtypes
![[ Visit Client Website ]](images/banner.jpg)
